What question did this study set out to answer?

To analyze the biological contributions of combining polatuzumab vedotin with glofitamab in treating R/R LBCL.

Abstract A026: Uncovering the biological contribution of polatuzumab vedotin when combined with glofitamab in R/R large B-cell lymphoma

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial reveals improved efficacy of Glofitamab-Polatuzumab in high-risk R/R LBCL, suggesting biological advantages.

To analyze the biological contributions of combining polatuzumab vedotin with glofitamab in treating R/R LBCL.
Patients treated with Glofit-Pola and Glofit monotherapy were analyzed for biomarkers using flow cytometry and RNA sequencing.
The study included patients from two clinical trials: NCT03533283 for Glofit-Pola and NCT03075696 for Glofit mono.
Statistical methods included gene set variation analysis and inverse probability weighting for comparison.
High complete response rates were noted for Glofit-Pola across molecular subtypes (e.g., 73.1% for ABC).
In high-risk patients, high proliferation signatures were linked to shorter PFS in Glofit mono (E2F HR 1.58), but longer PFS in Glofit-Pola (E2F HR 0.62).
T-cell activation increased and exhaustion markers decreased by cycle 4 in Glofit-Pola, indicating enhanced T-cell activation compared to Glofit mono.

Leung et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark